Red Light for Muscle Recovery: What the Trials Actually Show

Pre-exercise photobiomodulation therapy (PBMT), often marketed as red-light therapy, appears to reduce exercise-induced muscle soreness. The harder question is whether making the first workout hurt less also weakens the body's adaptation to it. One small randomized trial offers reassuring evidence, but it does not settle the question of long-term muscle growth or strength.

The best current summary is encouraging but provisional: a 2025 meta-analysis of 19 randomized controlled trials, including 672 participants, found that pre-exercise PBMT reduced soreness by an average of 12.27 points versus sham or control treatment (95% CI, −18.14 to −6.40; I²=48%). The result was statistically significant, but the review rated the certainty of evidence as low. That distinction matters. The pooled result supports an effect; it does not give athletes a precise, universal dose or guarantee the same payoff from every panel, laser, muscle group, or workout.

The recovery signal is real, but the estimate is fuzzy

In the 2025 systematic review and meta-analysis by Canez et al., PBMT was applied before exercise. Across differing wavelengths, energy densities, application sites, muscle groups, and exercise protocols, participants reported less post-exercise soreness than those receiving sham treatment or control care. Moderate heterogeneity (I²=48%) means the trials did not all land on the same effect size. The average is useful; it is not a prescription.

The review also reported better muscle-performance recovery at 24 hours after exercise-induced muscle damage, although the available report did not provide a pooled performance effect size. That leaves an important practical gap. Less soreness can make training feel easier, but soreness and performance are separate outcomes. A useful recovery tool should ideally improve both, and this review cannot quantify the performance benefit.

PBMT was the only one of three recovery approaches in the review to produce a statistically significant soreness result. Neuromuscular electrical stimulation had a mean difference of −4.60 points (95% CI, −20.03 to 10.83), while intermittent pneumatic compression had a mean difference of −2.20 (95% CI, −10.08 to 5.68). Both confidence intervals crossed zero, so neither comparison established a benefit. The pneumatic-compression result had moderate-certainty evidence of no significant effect in this analysis.

That does not prove red light beats every recovery practice in every setting. It does show that, in this particular evidence synthesis, PBMT had the strongest signal among the three modalities tested.

The adaptation question has one direct test

Recovery interventions make athletes nervous for a sensible reason: some strategies that dampen the immediate aftermath of training may also alter signals involved in adaptation. PBMT has one direct test of whether it interferes with the repeated bout effect—the reduced damage and functional disruption that usually follow a second exposure to the same unfamiliar eccentric exercise.

In a 2022 randomized trial by Padoin et al., 28 participants were assigned to pre-exercise LED treatment at 630 nm, 940 nm, or placebo before completing 100 drop-jumps. The red-light group received 4.6 J/cm² and 97 J total; the near-infrared group received 4.6 J/cm² and 114 J total.

After the first bout, the 940-nm treatment significantly attenuated creatine kinase at 72 hours versus placebo (P<0.01). Creatine kinase is a blood marker associated with muscle damage; it is not a direct measure of training adaptation or future hypertrophy. Squat-jump performance also showed an overall treatment effect (F=7.12; P=0.001): 630 nm performed better at 24 hours, while 940 nm performed better at 48 hours.

Fourteen days later, participants repeated the identical drop-jump protocol without LED treatment. The researchers found no between-group differences in any measured outcome. All groups showed the expected repeated bout effect. This result is compatible with the idea that first-bout PBMT protection did not prevent short-term adaptation to that exercise.

The trial is reassuring, not definitive. A lack of between-group differences in a 28-person study does not demonstrate equivalence with the same confidence that a well-powered equivalence trial would.

Each group contained only about nine or 10 people. That makes the second-bout null result especially fragile: the study may have lacked power to detect a meaningful difference. No independent trial in this evidence base has replicated the finding, and no study here tracks hypertrophy, maximal strength, or cumulative adaptation across a training block. "No gains blunted" goes well beyond the data.

Even the key trial did not improve every outcome

The Padoin trial contains an important counterweight to the meta-analysis. Participants did not report significant between-group differences in delayed-onset muscle soreness at any time point, despite the favorable pooled soreness result in Canez et al. Countermovement-jump performance also showed no significant treatment effect, while squat-jump performance did.

Those tests both assess lower-limb power, but they do not ask exactly the same thing of the athlete. The countermovement jump uses a greater stretch-shortening-cycle contribution than the squat jump. The study did not establish why one improved and the other did not. More simply, PBMT did not improve every marker after 100 drop-jumps.

The mismatch may reflect the exercise model, the device protocol, random variation in a small sample, or differences among the trials pooled in the meta-analysis. It prevents a blanket claim that PBMT reliably eliminates soreness or restores all forms of performance after plyometric work.

Wavelength and timing remain unsettled

The Padoin protocol suggests that wavelength may affect the timing and type of response. Near-infrared 940 nm performed better for the creatine kinase result at 72 hours, whereas red 630 nm performed better for squat-jump performance at 24 hours. Near-infrared light may reach deeper tissue than red light, but the trial did not measure tissue penetration, mitochondrial activity, or any other mechanism that could explain the split.

PBMT is often explained through photon absorption by cytochrome c oxidase in mitochondria, with downstream changes in ATP production and reactive oxygen species. Reviews in other clinical contexts describe that proposed pathway, including a 2025 review of low-level laser therapy and a review of low-level light therapy mechanisms. Those papers support biological plausibility, not proof that this pathway caused the recovery results after eccentric exercise. No human EIMD study cited here measured cytochrome c oxidase activation, ATP output, or reactive oxygen species after PBMT.

Timing also remains an open question. The strongest pooled evidence concerns treatment before exercise. A 2024 randomized trial in competitive rugby athletes examined PBMT at different times around exercise, but the available abstract does not provide enough timing-specific between-group data to determine whether pre-exercise use beats post-exercise use. Buying a device because it has a "post-workout recovery" mode would therefore be shopping ahead of the evidence.

What athletes can reasonably do now

Athletes who accept low-certainty evidence can reasonably consider pre-exercise PBMT on the muscles they expect to work, particularly when reducing soreness or improving short-term recovery would help training logistics. The clearest protocol in the direct repeated-bout trial used 4.6 J/cm², but that is a study-specific setting, not an established optimum. Device output, treatment area, total energy, wavelength, and application method all vary.

Expect a possible reduction in soreness, not a guaranteed performance rescue. Do not infer long-term hypertrophy, strength gains, or proven protection of all training adaptations from a two-week repeat-bout result. A broader 2025 umbrella review of PBM trials shows that photobiomodulation has been studied across many health conditions, but breadth of research does not answer the specific athletic question better than EIMD trials do.

The evidence supports a cautious verdict: pre-exercise PBMT probably helps soreness after muscle-damaging exercise, and one small trial found no sign that it disrupted the repeated bout effect over 14 days. That makes it a plausible recovery experiment for an athlete, not a license to promise preserved gains over months of training.